Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer

Janssen, Jorien B.E.; Medema, Jan Paul; Gootjes, Elske C.; Tauriello, Daniele V.F.; Verheul, H.

doi:10.1016/j.ctrv.2022.102433

Cited by 19 publications

(11 citation statements)

References 130 publications

(156 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…228 In patients with mCRC, the proportions of KRAS, NRAS, and HRAS mutations are 40%-50%, 2%-9%, and 1%-2%, respectively. 229 The KRAS proto-oncogene encodes a GTPase protein (KRAS) that is crucial in copious molecular pathways including the EGFR pathway. 230 With high-frequency occurrence in CRC KRAS mutations, KRAS G12V is related to multiple aspects of tumor clinical pathology, such as invasion and poor prognosis.…”

Section: Tre Atment S Tr Ategymentioning

confidence: 99%

“…Approximately 45% of colon cancer cells present RAS mutations 228 . In patients with mCRC, the proportions of KRAS, NRAS, and HRAS mutations are 40%–50%, 2%–9%, and 1%–2%, respectively 229 . The KRAS proto‐oncogene encodes a GTPase protein (KRAS) that is crucial in copious molecular pathways including the EGFR pathway 230 .…”

Section: Treatment Strategymentioning

confidence: 99%

See 1 more Smart Citation

Anti‐angiogenesis in colorectal cancer therapy

Yang,

Zhang,

Bai

et al. 2024

Cancer Science

View full text Add to dashboard Cite

The morbidity of colorectal cancer (CRC) has risen to third place among malignant tumors worldwide. In addition, CRC is a common cancer in China whose incidence increases annually. Angiogenesis plays an important role in the development of tumors because it can bring the nutrients that cancer cells need and take away metabolic waste. Various mechanisms are involved in the formation of neovascularization, and vascular endothelial growth factor is a key mediator. Meanwhile, angiogenesis inhibitors and drug resistance (DR) are challenges to consider when formulating treatment strategies for patients with different conditions. Thus, this review will discuss the molecules, signaling pathways, microenvironment, treatment, and DR of angiogenesis in CRC.

show abstract

Section: Tre Atment S Tr Ategymentioning

confidence: 99%

Section: Treatment Strategymentioning

confidence: 99%

Anti‐angiogenesis in colorectal cancer therapy

Yang,

Zhang,

Bai

et al. 2024

Cancer Science

View full text Add to dashboard Cite

show abstract

“…Recently, anti‐EGFR (epidermal growth factor receptor) monoclonal antibody has been used as the first‐line targeted therapy for CRC. KRAS and NRAS mutations, occurring in 45% of CRC, cause primary resistance to anti‐EGFR therapy 92,93 . Thus, it is important to screen potential drugs for KRAS or NRAS mutant CRC using the PDX platform.…”

Section: The Application Of Pdx In Crc Researchmentioning

confidence: 99%

“…KRAS and NRAS mutations, occurring in 45% of CRC, cause primary resistance to anti‐EGFR therapy. 92 , 93 Thus, it is important to screen potential drugs for KRAS or NRAS mutant CRC using the PDX platform. GC1118, an anti‐EGFR antibody, exhibits promising therapeutic efficacy against KRAS mutation‐driven PDX.…”

Section: The Application Of Pdx In Crc Researchmentioning

confidence: 99%

Patient‐derived xenograft model in colorectal cancer basic and translational research

Liu

Xin

Wang

2022

Anim Models and Exp Med

View full text Add to dashboard Cite

Colorectal cancer (CRC), one of the most deadly cancers, is the fourth most common cause of cancer-related deaths. 1 Currently, surgery is the main treatment option for primary and metastatic CRC, and chemotherapy and targeted drugs are regularly used as adjuvant regimens. [2][3][4] Despite improvements in screening and treatment, the number of individuals newly diagnosed is increasing rapidly. Moreover, metastasis, recurrence, and chemoresistance are common in CRC patients after treatment, which leads to the dismal prognosis and high mortality of CRC patients. [5][6][7] These issues lead to the need for more advancements in CRC treatment. About 5% of CRCs are hereditary tumor syndromes, such as familial adenomatous polyposis (FAP) and Lynch syndrome. 8 Most of the CRCs are sporadic as the comprehensive effects of various factors, including somatic genetic alterations, chronic inflammation, lifestyle, and environmental stimuli. 9 These genetic and nongenetic risk factors work together to promote CRC development and progression. [10][11][12][13] To date, the mechanisms involved in the interactions of these factors driving CRC development and progression are

show abstract

“…Despite the increasing use and tremendous success of molecular biomarkers as proven tools for patient and treatment selection in the treatment of CRC (e.g., ERBB2, RAS, BRAF, TP53, APC), [21][22][23][24] relatively few studies have explored the role of molecular status in response to CRS in CRC-PM patients. Therefore, this review aims to provide an overview of the altered molecular status of CRC-PM patients treated with CRS and to assess the role of these molecular biomarkers in patient selection, the guidance of combination therapy, patient outcomes, and patient prognosis prediction in CRS treatment.…”

mentioning

confidence: 99%

Impact of Molecular Status on Cytoreductive Surgery for Peritoneal Metastases from Colorectal Cancer

Zhong

Yang

Qin

et al. 2023

Clin Colon Rectal Surg

View full text Add to dashboard Cite

Colorectal cancer peritoneal metastases (CRC-PM) are present in 5 to 15% of instances of CRC, and the overall survival (OS) of patients with CRC-PM is much lower than that of patients with other isolated metastatic locations. In recent years, the introduction of cytoreductive surgery (CRS) in conjunction with hyperthermic intraperitoneal chemotherapy has resulted in a significant improvement in CRC-PM patients' OS. Despite this, a significant proportion of CRS patients continue to suffer complications of grades III to V or even die during the perioperative period. Early diagnosis, optimization of patient selection criteria, and refining of individualized combination therapy are necessary for these patients. In this review, we evaluate studies examining the relationship between molecular status and CRS in CRC-PM. Our objective is to gain a comprehensive understanding of how the altered molecular status of CRC-PM impacts CRS, which could increase the likelihood of tailored therapy in the future.

show abstract

Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer

Cited by 19 publications

References 130 publications

Anti‐angiogenesis in colorectal cancer therapy

Anti‐angiogenesis in colorectal cancer therapy

Patient‐derived xenograft model in colorectal cancer basic and translational research

Impact of Molecular Status on Cytoreductive Surgery for Peritoneal Metastases from Colorectal Cancer

Contact Info

Product

Resources

About